SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
IN PARTNERSHIP WITH DIA
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
March 17, 2026
 · 
1 min read
 · 
BioSpace Insights
Prohibition sign. Halftone hands cross their fingers in a no entry sign. Refusal, stop gesture. Rejection sign. Warning concept. Newspaper collage
FDA
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
March 17, 2026
 · 
2 min read
 · 
Heather McKenzie
Creative photo collage or modern art collage featuring symbols of law and justice. Hand holding a gavel and scales of justice with books about law.
Legal
Kennedy’s Vaccine Policy Overhaul Stymied by Federal Judge
March 17, 2026
 · 
3 min read
 · 
Tristan Manalac
Government
As Midterms Loom, White House Cracks Down on RFK Jr.’s Vaccine Policies—but MAHA Resists
March 16, 2026
 · 
4 min read
 · 
Tristan Manalac